Fra-1 promotes breast cancer chemosensitivity by driving cancer stem cells from dormancy

38Citations
Citations of this article
43Readers
Mendeley users who have this article in their library.

Abstract

Fra-1 is a member of the Fos transcription factor family that is highly expressed in multiple cancers, playing important roles in transformation, proliferation, and metastasis. In this study, we observed an inverse correlation between the expression of Fra-1 in human stage II breast cancer tissues and the corresponding level of clinical chemoresistance. Extending these findings in vitro, we found that knockdown of Fra-1 in breast tumor cells was sufficient to confer resistance to doxorubicin and cyclophosphamide, whereas enhanced Fra-1 expression could render these cells chemosensitive. The tumor cell side population, which is enriched for cancer stem cells, was found to be associated with chemoresistance. Increased side population fractions were detected among tumor cell lines subjected to Fra-1 knockdown. In contrast, enhanced expression of Fra-1 was correlated with a decreased side population fraction, and significantly, this finding was recapitulated in vivo, where tumors with enhanced expression of Fra-1 were found to have blunted growth. Tumor cells subjected to Fra-1 knockdown grew faster and were larger in size. Taken together, our findings suggest that Fra-1 may be an important prognostic marker for breast cancer therapy. ©2012 AACR.

Cite

CITATION STYLE

APA

Lu, D., Chen, S., Tan, X., Li, N., Liu, C., Li, Z., … Xiang, R. (2012). Fra-1 promotes breast cancer chemosensitivity by driving cancer stem cells from dormancy. Cancer Research, 72(14), 3451–3456. https://doi.org/10.1158/0008-5472.CAN-11-2536

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free